An Open-label, Phase 1b Multicenter Study of IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Sintilimab (Primary)
- Indications Endometrial cancer; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Innovent Biologics
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Aug 2019 Planned number of patients changed from 80 to 50.
- 13 Aug 2019 Planned End Date changed from 1 May 2022 to 1 Aug 2022.